The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor

Christine Bolitho, Michael A Hahn, Robert C Baxter and Deborah J Marsh

Hormones and Cancer Group, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, E25, St Leonards, New South Wales 2065, Australia

(Correspondence should be addressed to D J Marsh; Email: deborah.marsh@sydney.edu.au)

Abstract

The chemokine CXCL1 is elevated in plasma and ascites from patients with ovarian cancer. We have previously shown that CXCL1 is a marker of phosphatidylinositol 3-kinase signalling in epithelial ovarian cancer (EOC) cell lines, a pathway that is commonly activated in ovarian tumours. To investigate whether CXCL1 also has functional significance in ovarian cancer, this chemokine was either down-regulated using siRNAs or overexpressed by transfection of CXCL1 into the EOC cell lines SKOV3 and OVCAR-3 and proliferation assessed over 7 days. Overexpression of CXCL1 increased proliferation of ovarian cancer cells over 7 days, while down-regulation was inhibitory. Treatment of cells with recombinant CXCL1 induced epidermal growth factor receptor (EGFR) phosphorylation at Y1068, indicating crosstalk between the CXCL1 G-protein-coupled receptor CXCR2 and the EGFR. CXCL1-induced proliferation was also decreased by inhibition of EGFR kinase activity and was dependent on extracellular matrix metalloproteinase-mediated release of heparin-binding EGF (HB-EGF). Involvement of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase 1/2 (ERK1/2) signalling was also evident since inhibition of both Ras and MEK activity decreased CXCL1-induced proliferation. CXCL1-induced ERK1/2 phosphorylation was inhibited by the MEK1 inhibitor PD98059; however, EGFR phosphorylation was unaffected, indicating that CXCL1 activation of MAPK signalling is downstream of the EGFR. Taken together, these data show that CXCL1 functions through CXCR2 to transactivate the EGFR by proteolytic cleavage of HB-EGF, leading to activation of MAPK signalling and increased proliferation of EOC cells.

Endocrine-Related Cancer (2010) 17 929–940

Introduction

Ovarian cancer accounts for ~4% of cancers in women and has the highest mortality rate of the gynaecological malignancies (Schildkraut & Thompson 1988, Parkin et al. 2005). Five year survival is <30% for patients with late stage disease, but increases to around 90% for women diagnosed in the early stages of this disease (Jacobs & Menon 2004). Currently, the most common test used to aid in the diagnosis of epithelial ovarian cancer (EOC) is serum measurement of the glycoprotein CA-125. While this test has high sensitivity, it also has low specificity (Bast et al. 1983, Jacobs & Bast 1989, Jacobs & Menon 2004).

Factors explored as potential serum markers of ovarian cancer include insulin-like growth factor binding protein-2 (Baron-Hay et al. 2004), interleukin 7 (IL7; Lambeck et al. 2007) and more recently, the combined use of β2-microglobulin, apolipoprotein A-1, transthyretin, and transferrin with CA-125, significantly improving the detection of early stage ovarian cancer (Kozak et al. 2005, Nosov et al. 2009, Fung 2010). This has led to development of the FDA-approved Ovarian Tumour Triage Test, known as OVA1 (Vermillion, Fremont, CA, USA), which is recommended for use in conjunction with imaging and physical examination, but not as an isolated diagnostic test (Fung 2010).
The phosphatidylinositol 3-kinase (PI3-K) signalling pathway is commonly activated in EOC, and many of its components are implicated in increased cell survival and proliferation (Shayesteh et al. 1999). We recently investigated the involvement of PI3-K signalling in the regulation of secreted proteins in EOC cells by proteomic profiling using surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS), and identified the chemokine (C-X-C motif) ligand 1 (CXCL1) as a marker of PI3-K signalling in conditioned media from five EOC cell lines (Moscova et al. 2006).

CXCL1, also known as melanoma growth stimulating activity or Gro-α, is a member of the CXC chemokine family that binds to and activates the G-protein-coupled receptor (GPCR) CXCR2 (Balkwill 2004). This chemokine was first isolated from the human melanoma cell line HS0294 (Richmond et al. 1983) and subsequently from human melanoma tumours (Richmond & Thomas 1988), and promotes tumour progression (Richmond et al. 1983, 1985, Bordoni et al. 1989, 1990, Shattuck et al. 1994, Luan et al. 1997).

CXCL1 has been implicated in normal ovulation and is detected in follicular fluid as well as in ovarian stromal and granulosa lutein cells (Oral et al. 1997, Karstrom-Encrantz et al. 1998). In ovarian cancer cells, CXCL1 is up-regulated by MTAL, a metastasis-associated gene (Dannenmann et al. 2008), lysophosphatidic acid (Lee et al. 2006) and Ras (Yang et al. 2006). In addition, elevated CXCL1 has been reported in plasma, serum, ascites and tumour tissue of ovarian cancer patients (Lee et al. 2006, Yang et al. 2006, Wang et al. 2008). Since CXCL1 is up-regulated in ovarian cancer (Moscova et al. 2006), we sought to determine whether elevated levels of this chemokine might have an autocrine role in EOC by influencing cell growth via key signalling pathways.

Recent reports have demonstrated that many GPCR agonists may induce transactivation of the epidermal growth factor receptor (EGFR), suggesting crosstalk between chemokine and growth factor pathways to induce proliferation (Carpenter 1999, 2000, Bhola & Grandis 2008, Liebmann 2010). One mechanism of EGFR transactivation by GPCRs is through the matrix metalloproteinase (MMP)-mediated release of membrane-bound EGFR ligands, such as heparin-binding EGF-like growth factor (HB-EGF), that subsequently activate the EGFR (Prenzel et al. 1999, Schafer et al. 2004). The EGFR can also be transactivated intracellularly via Src signalling (Andreev et al. 2001, Guerrero et al. 2004, Li et al. 2006). Since CXCL1 signalling occurs through a GPCR, we investigated whether CXCL1 may transactivate the EGFR, leading to increased proliferation in EOC.

Materials and methods

Cell lines and reagents

The human EOC cell lines SKOV3 and OVCAR-3 were obtained from the American Type Culture Collection (Manassas, VA, USA). Anti-human HB-EGF neutralising antibodies were obtained from R&D Systems (Minneapolis, MN, USA), and rabbit anti-phospho-EGFR (Y1068) was purchased from Invitrogen Australia. Rabbit anti-total EGFR, total Akt and phospho-Akt (S473), total extracellular signal-regulated kinase 1/2 (ERK1/2), phosphorylated ERK1/2, total Src, phospho-Src (Y416) and phospho-Src (Y527), phospho-EGFR (Y845) and phospho-EGFR (Y1173) were obtained from Cell Signalling Technology (Beverly, MA, USA). Inhibitors SB225002, PD98059, PD153035 and GM6001 were purchased from Calbiochem (San Diego, CA, USA), and FTI-277 was purchased from Sigma–Aldrich. Two sources of human recombinant CXCL1 were used: Millipore (North Ryde, NSW, Australia: discontinued) and R&D Systems. EGF and protease inhibitor cocktail (cat #P8340) were purchased from Sigma–Aldrich. Amaxa Cell Line Nucleofector Kit V from Lonza Cologne AG was purchased from Quantum Scientific (Lane Cove, NSW, Australia). Enhanced chemiluminescence (ECL) reagents, Supersignal West Dura extended duration and Pico chemiluminescent substrate reagents were obtained from Thermoscientific (Rockford, IL, USA). Restriction enzymes BspTI (AflII) and NotI were obtained from Fermentas Life Sciences (Burlington, Ont., Canada).

Cell culture

SKOV3 and OVCAR-3 cells were cultured in RPMI 1640 medium (Gibco, Invitrogen) supplemented with 10% FCS (Gibco or SAFC Biosciences, Brooklyn, VIC, USA) and 0.3 mg/l glutamine (Gibco) at 37 °C in 5% CO2.

Overexpression of CXCL1

S sense and antisense oligonucleotides were designed to amplify CXCL1 cDNA: forward 5′-TAATCTTAGATGGCCCGCGTTGGTCTCTC-3′ and reverse 5′-TGCTCGGCGCAGTTTTGTCACTGT-3′ (Sigma–Aldrich). CXCL1 cDNA was PCR amplified from RNA extracted from the prostate cancer cell line PC3 using AccuPrime Pfx (Invitrogen). The BspTI (AflII) site (underlined) within the forward primer and the NotI site (underlined) in the reverse primer were used to directionally clone the PCR product into the mammalian expression vector pcDNA4/TO.
(Invitrogen). Integrity of the pcDNA4/CXCL1 construct was verified by sequence analysis (Supamac; Sydney University, NSW, Australia) with CXCL1 sequence compared with NCBI Genbank Accession number NM_001511.2. To determine the effect of CXCL1 overexpression upon proliferation of ovarian cancer cells, 1.0×10⁶ SKOV3 or OVCAR-3 cells were transfected with 5 μg of empty vector or pcDNA4/CXCL1 by nucleofection (Nucleofector Kit V, program V-005 for SKOV3 cells and program A-023 for OVCAR-3 cells; Lonza Cologne AG, Germany).

siRNA down-regulation of CXCL1

siRNA targeted against CXCL1 was custom designed by Qiagen (HP Guaranteed siRNA: target mRNA sequence: 5'-CAGUGUUUCUGCUAGAA-3'). A generic non-silencing siRNA with no known sequence homology (target mRNA sequence: 5'-UUCUCGA-ACGUGUACGU-3'; Qiagen) was used as a negative control. In total, 1.0×10⁶ SKOV3 or OVCAR-3 cells were transfected by nucleofection with 2 μM of either CXCL1 or non-silencing siRNA (Nucleofector Kit V, program V-005 for SKOV3 cells and program A-023 for OVCAR-3 cells).

Down-regulation of CXCL1 mRNA was assessed by quantitative real-time PCR (qRT-PCR) using Taqman Gene Expression Assays (CXCL1: HS00256937_m1; Applied Biosystems, Foster City, CA, USA) and Taqman Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems) on a Rotor-Gene 3000 thermal cycler (Corbett Research, Mortlake, NSW, Australia). The reference gene hydroxymethylbilane synthase (HMBS; Hs00609297_m1) was used for normalisation, and results were expressed as CXCL1:HMBS. Assays were performed in triplicate, and data were analysed using the ΔΔCt method (Rotor-Gene 6 Analysis Software; Corbett Life Sciences) expressed relative to non-silencing control siRNA-transfected samples.

Proliferation assays

SKOV3 and OVCAR-3 cells transfected with siRNA, CXCL1 expression construct or empty vector as described above were plated at 1.0–2.0×10⁶ cells per well into 48-well tissue culture plates. Proliferation was assessed by direct cell counts at days 2, 4 and 7, expressed as relative cell numbers with the total number of cells on day 7 for either non-silencing siRNA-transfected cells or empty vector-transfected cells expressed as 100. At each time point, the concentration of secreted CXCL1 in cultured supernatants was monitored using a Human CXCL1/Gro-α Quantikine sandwich ELISA kit (R&D Systems), according to the manufacturer's instructions. Data were calculated as fold difference relative to CXCL1 concentration in the non-silencing siRNA- or empty vector-transfected control at day 2. A Human IL8 Quantikine sandwich ELISA kit was also purchased from R&D Systems.

Signalling pathways

SKOV3 and OVCAR-3 cells were plated in triplicate into 48-well tissue culture plates at 1.0–2.0×10⁴ cells/well and treated with recombinant CXCL1 alone (100 ng/ml in 10% FCS media) or recombinant CXCL1 in the presence of either CXCRI2 inhibitor SB225002 (200 nM), EGFR inhibitor PD153035 (100 nM), MEK1 inhibitor PD98059 (10 μM), farnesyltransferase inhibitor FTI-277 (10 μM), pan-MMP inhibitor GM6001 (200 nM) or HB-EGF neutralising antibody (4 μg/ml). In some experiments, gefitinib (200 nM; AstraZeneca, Macclesfield, UK) was alternatively used to inhibit EGFR kinase activity. EGF (50 ng/ml) was used as a positive control in experiments investigating transactivation of the EGFR by CXCL1. Untreated and inhibitor-only controls were included, and treatments replenished every 2–3 days.

Western blot analysis

SKOV3 cells were seeded into 6-well tissue culture plates (2.0×10⁵ cells/well) for 24 h, serum starved in media containing 0.5% BSA for a further 24 h, then stimulated with recombinant CXCL1 (100 ng/ml) for up to 120 min. A 5-min treatment of cells with EGF (50 ng/ml) was used as a positive control for EGFR phosphorylation. For experiments investigating mitogen-activated protein kinase (MAPK) signalling, SKOV3 cells were pretreated with PD98059 (10 μM) for 30 min before treatment with CXCL1 (100 ng/ml) for 5–120 min or EGF (50 ng/ml) for 5 min. After treatment, cells were washed with ice-cold PBS and lysed in 200 μl of chilled SDS sample buffer (62.5 mM Tris (pH 6.8)), 20 g/l SDS, 10% glycerol, 50 mM dithiothreitol and 0.01% bromophenol blue containing 1% v/v protease inhibitor cocktail (Sigma–Aldrich) at 4 °C for 10 min. Cell lysates were sonicated for 30 s, and proteins were separated using 4–12% Bis–Tris SDS-PAGE gels (Invitrogen) and transferred to Hybond C nitrocellulose (GE Healthcare Life Sciences, Rydalmere, NSW, Australia) for western analysis. After transfer, membranes were blocked using 5% milk in Tris-buffered saline-T (TBS-T; 20 mM Tris–HCl, pH 7.5, 150 mM NaCl and 0.1% Tween 20) and probed with primary antibodies diluted
in TBS-T containing 5% BSA overnight at 4 °C. Membranes were washed with TBS-T for 1 h before incubating with a HRP-conjugated secondary antibody (diluted 1:5000 in 5% milk in TBS-T) for 1 h at room temperature before washing again in TBS-T and detection of bound antibodies by ECL using SuperSignal West Pico and Dura substrates (Pierce, Rockford, IL, USA). Total and phosphorylated proteins were analysed on replicate blots. Membranes were also probed with α-tubulin antibody as a loading control. Images were recorded using the Fujifilm LAS-4000 imaging system (Berthold Australia Pty Ltd, Bundoora, VIC, Australia). Densitometry of bands was performed using Multigauge software (v3.0; Fujifilm Australia Pty Ltd, Brookvale, NSW, Australia), and data were expressed as the ratio of phosphorylated to total protein.

**Statistical analysis**

Data analyses were performed using SPSS software 16.0 (SPSS Australasia Pty Ltd, Chatswood, NSW, Australia). Data are expressed as mean ± S.E.M. from at least three independent experiments. Statistical significance for western blot analysis and proliferation experiments was determined by one-way ANOVA and repeated-measures ANOVA respectively. P < 0.05 was considered statistically significant.

**Results**

**Overexpression of CXCL1 increases EOC cell proliferation**

To investigate whether CXCL1 influenced EOC cell proliferation, a CXCL1 expression construct was transfected into SKOV3 and OVCAR-3 cells and proliferation assessed over 7 days. Relative to empty vector control, CXCL1 overexpression led to increased cell proliferation in both cell lines: for SKOV3, 38.9 ± 16.9% increase at day 7 (P < 0.005); for OVCAR-3, 53.6 ± 3.6% increase (P < 0.05; Fig. 1A and B). Secreted CXCL1 in CXCL1-transfected cells also increased over this time period relative to empty vector. At day 7, SKOV3-secreted CXCL1 levels in empty vector cells were 40.2 ± 4.4 ng/ml compared to 77.1 ± 9.0 ng/ml in cells transfected with the CXCL1 construct (P < 0.001); OVCAR-3-secreted CXCL1 levels in empty vector cells were 2.2 ± 0.9 ng/ml compared to 98.4 ± 37.4 ng/ml in cells transfected with the CXCL1 construct (P < 0.002; Fig. 1C and D).

**Down-regulation of CXCL1 reduces EOC cell proliferation**

As overexpression of CXCL1 increased proliferation of ovarian cancer cells, we investigated whether down-regulation of CXCL1 by siRNA would reduce proliferation. Approximately 60% of CXCL1 transcript was down-regulated by CXCL1 siRNA at day 3 in both SKOV3 and OVCAR-3 cells (Supplementary Figure 1, see section on supplementary data given at the end of this article and data not shown). Secreted CXCL1 in cells transfected with CXCL1 siRNA was decreased relative to cells transfected with a non-silencing siRNA in both cell lines: for SKOV3, 70.2 ± 3.8% reduction (day 2), 61.5 ± 7.1% (day 4) and 58.0 ± 4.8% (day 7); for OVCAR-3, 80.5 ± 4.2% reduction (day 2), 71.4 ± 2.1% (day 4) and 58.8 ± 11.6% (day 7) (Fig. 1A and B). We had previously shown that IL8, also known as CXCL8, is a secreted
marker of PI3-K signalling in EOC cell lines (Moscova et al. 2006). Like CXCL1, IL8 signals through the receptor CXCR2. Down-regulation of CXCL1 did not affect secreted levels of IL8 (Supplementary Figure 2, see section on supplementary data given at the end of this article).

A reduction in cellular proliferation was observed over 7 days in both cell lines following down-regulation of CXCL1 by siRNA compared to control cells (Fig. 2C and D; P < 0.0001). Addition of recombinant CXCL1 (100 ng/ml) to CXCL1 siRNA-transfected cells restored proliferation to levels similar to that seen in control cells, while a further increase in proliferation was observed when recombinant CXCL1 (100 ng/ml) was added to cells transfected with the non-silencing siRNA in both cell lines (P < 0.00001; Fig. 2C and D).

To confirm the receptor dependence of CXCL1 action, SKOV3 and OVCAR-3 cells were stimulated with recombinant CXCL1 (100 ng/ml) either in the presence or absence of the CXCR2 inhibitor, SB225002 (200 nM) and cell proliferation assessed over 7 days. CXCL1-induced proliferation at day 7 in both cell lines was inhibited by SB225002 (P < 0.0001; Fig. 2E and F), confirming that CXCL1-induced proliferation is mediated through CXCR2.

**Transactivation of the EGFR by CXCL1**

To investigate possible crosstalk between CXCR2 and the EGFR, SKOV3 and OVCAR-3 cells were stimulated with recombinant CXCL1 (100 ng/ml) in the presence of the EGFR inhibitor PD153035 (100 nM). Cells were also stimulated with EGF (50 ng/ml) as a positive control. CXCL1-induced proliferation in both cell lines was completely blocked by inhibition of EGFR kinase activity (P < 0.0001; Fig. 3A and B). A similar result was seen with an alternative EGFR inhibitor (gefitinib, 200 nM; data not shown). Stimulation of SKOV3 cells with recombinant CXCL1 (100 ng/ml) induced a peak of EGFR tyrosine phosphorylation at Y1068 which was significant at 5 min (P < 0.05) but not at 15 min, exhibiting a second wave of phosphorylation reaching a twofold increase at 120 min (P < 0.0002; Fig. 3C and D). This biphasic response was observed in four of six experiments. Furthermore, CXCL1-induced phosphorylation at Y1068 was inhibited by treatment with either the pan-MMP inhibitor GM6001 or the EGFR inhibitor PD153035 (Supplementary Figure 3, see section on supplementary data given at the end of this article).

Increased phosphorylation at Y1068 could not be robustly determined in OVCAR-3 cells as the phosphorylation signal detected by western blot was only weakly detectable under conditions where it was observed in SKOV3 cells. EGFR phosphorylation at Y845 and Y1173 was not observed in SKOV3 cells in response to stimulation with CXCL1; however, these sites were phosphorylated in response to treatment with EGF (Supplementary Figure 4, see section on supplementary data given at the end of this article). Taken together, this suggests that CXCL1-induced proliferation of EOC cells is mediated through EGFR transactivation.
Since CXCL1 expression is induced by PI3-K pathway activation and EGFR signalling activates PI3-K in ovarian cancer cell lines (Moscova et al. 2006), the possibility of a positive feedback loop occurring where CXCL1 regulates its own production by also activating PI3-K signalling was investigated. Serum-deprived SKOV3 cells were treated with CXCL1 (100 ng/ml) for 5–120 min, and PI3-K signalling was investigated by immunoblot for total and phosphorylated Akt (S473). No phosphorylation of Akt (S473) was detected following CXCL1 stimulation (100 ng/ml) above basal levels at any of the time points investigated (data not shown), suggesting that although CXCL1 transactivates the EGFR, it does not activate PI3-K signalling and is unlikely to induce a positive feedback loop to activate its own production.

**CXCL1-stimulated proliferation involves Ras and MAPK signalling**

To investigate possible signalling pathways downstream of the EGFR, SKOV3 cells were treated with recombinant CXCL1 (100 ng/ml) for 5–120 min. Phosphorylation of ERK1/2 was seen after CXCL1 stimulation, with a 2.5-fold increase in phosphorylated ERK1/2 observed after 15 min of CXCL1 treatment ($P<0.001$), returning to basal levels by 120 min (Fig. 4A). A 30-min pretreatment of SKOV3 cells with the MEK1 inhibitor PD98059 (10 μM) completely inhibited both basal and CXCL1-induced ERK1/2 phosphorylation (Fig. 4A). To determine whether CXCL1-induced MAPK signalling occurred upstream or downstream of the EGFR, SKOV3 cells were treated for 120 min with recombinant CXCL1 (100 ng/ml) either in the presence or absence of the MEK1 inhibitor PD98059 (10 μM), and lysates were probed for EGFR tyrosine phosphorylation at Y1068. As observed previously (Fig. 3C), CXCL1 induced EGFR phosphorylation at Y1068; however, there was no effect of PD98059 on CXCL1-induced EGFR phosphorylation indicating that CXCL1-induced EGFR transactivation likely occurs upstream of MAPK signalling (Fig. 4B). Treatment of SKOV3 cells with either the pan-MMP inhibitor GM6001 or the EGFR inhibitor PD153035 inhibited CXCL1-induced phosphorylation of ERK1/2, confirming that CXCL1-induced ERK1/2 activation occurred downstream of EGFR transactivation (Supplementary Figure 5, see section on supplementary data given at the end of this article).

To determine the role of MAPK signalling in CXCL1-induced proliferation, SKOV3 and OVCAR-3 cells were treated with CXCL1 (100 ng/ml) in the presence of the MEK1 inhibitor PD98059 (10 μM) and cell proliferation assessed over 7 days. Treatment of both cell lines with PD98059 completely inhibited CXCL1-induced proliferation ($P<0.0001$), without affecting basal proliferation (Fig. 5A and B). In addition, the involvement of Ras in CXCL1-induced proliferation was assessed by treatment of SKOV3 and OVCAR-3 cells with CXCL1 in the presence of the H- and K-Ras-specific inhibitor, FTI-277 (10 μM). CXCL1-induced proliferation was completely blocked by treatment with FTI-277 in both cell lines studied (Fig. 5C and D; $P<0.0001$). There was also an
inhibitory effect upon basal proliferation by FTI-277 in SKOV3 cells \( (P < 0.0001) \) but not in OVCAR-3 cells (Fig. 5C and D). These data indicate that CXCL1-induced proliferation in EOC cells involves signalling through Ras and MEK1.

**CXCL1-stimulated proliferation occurs via MMP-mediated release of HB-EGF**

One mechanism of transactivation of the EGFR in response to ligands of various GPCRs involves MMP-mediated release of membrane-bound EGFR ligands, such as HB-EGF (Prenzel et al. 1999, Itoh et al. 2005). To investigate the involvement of this mechanism in CXCL1-induced proliferation, SKOV3 and OVCAR-3 cells were treated with CXCL1 (100 ng/ml) in the presence of the pan-MMP inhibitor GM6001 (200 nM). CXCL1-induced proliferation was completely abolished in both cell lines after inhibition of MMP activity, with no effect on basal proliferation \( (P < 0.0001; \text{Fig. } 6A \text{ and } B) \). Similarly, treatment of cell lines with an HB-EGF neutralising antibody (4 µg/ml) in combination with recombinant CXCL1 (100 ng/ml) completely inhibited CXCL1-induced proliferation in both EOC cell lines (day 7, \( P < 0.0001 \)), again without affecting the basal proliferation rate (Fig. 6C and D). Isotype control IgG had no effect upon CXCL1-induced proliferation (data not shown). These data indicate that CXCL1-induced proliferation in EOC cells relies upon MMP-mediated cleavage of the membrane-bound EGFR ligand HB-EGF. In further support of this extracellular signalling mechanism, treatment of either cell line with recombinant CXCL1 did not lead to changes in phosphorylation of either the active (Y416) or inactive (Y527) forms of Src suggesting that CXCL1 does not activate intracellular signalling via Src (data not shown). Moreover, we have shown that EGFR phosphorylation at Y845, a site at which phosphorylation is mediated by c-Src, does not occur in response to treatment with CXCL1 (Supplementary Figure 4).

**Figure 4** CXCL1 induces EGFR phosphorylation independent of ERK1/2 transactivation. (A) Immunoblot for phosphorylated ERK1/2 (pERK1/2), total ERK1/2 (tERK1/2) and \( \alpha \)-tubulin expression of serum-deprived SKOV3 cells pretreated with (open bars) or without (closed bars) the MEK1 inhibitor, PD98059 (10 \( \mu \)M), for 30 min before treatment with CXCL1 (100 ng/ml) for 5–120 min. A 5-min treatment with EGF (50 ng/ml) was used as a positive control for ERK1/2 phosphorylation. Graph represents pooled data from four independent experiments with data calculated as pERK/tERK ratios and expressed as fold change relative to untreated control ± S.E.M. A 2.5-fold increase in pERK1/2 was observed 15 min after CXCL1 treatment, with both basal and CXCL1-induced ERK1/2 phosphorylation completely inhibited by PD98059, \( *P < 0.001 \). (B) Immunoblot for pEGFR (Y1068), tEGFR and \( \alpha \)-tubulin of SKOV3 cells pretreated with (open bars) or without (closed bars) PD98059 (10 \( \mu \)M) and treated with CXCL1 (100 ng/ml) for 120 min. Graph represents pooled data from three independent experiments, with data calculated as pEGFR/tEGFR ratios and expressed as fold change relative to untreated control ± S.E.M. CXCL1-induced EGFR phosphorylation was unaffected by MEK1 inhibition.

**Figure 5** CXCL1-induced proliferation requires MEK1 and Ras activity. Effect of MEK1 inhibition by PD98059 (10 \( \mu \)M) (A and B) and H- and K-Ras inhibition by FTI-277 (10 \( \mu \)M) (C and D) upon CXCL1-induced proliferation over 7 days in SKOV3 (A and C) and OVCAR-3 (B and D) cells was assessed. Graphs represent pooled data from four independent experiments expressed as relative cell number ± S.E.M. where total cell number in the untreated control at day 7 is expressed as 100. Inhibition of both MEK1 and Ras decreased CXCL1-induced proliferation in both cell lines indicating involvement of these pathways in CXCL1-induced EOC proliferation. Treatment with FTI-277 also resulted in an inhibitory effect upon basal proliferation in SKOV3 cells (C), \( *P < 0.0001, \#P < 0.0001 \).
C Bolitho et al.: CXCL1-induced proliferation in ovarian cancer

Discussion

We previously used a proteomic screen to identify CXCL1 as a chemokine regulated by PI3-K signalling in EOC cells (Moscova et al. 2006). Others have shown that CXCL1 levels are increased in serum, plasma, tumour tissue and ascites from women with ovarian cancer (Lee et al. 2006, Yang et al. 2006, Wang et al. 2008) suggesting a role for CXCL1 in ovarian cancer. Here, we have investigated whether elevated levels of CXCL1 have an autocrine role in EOC cells by influencing cell growth. Overexpression of CXCL1 increased cellular proliferation over 7 days in two ovarian cancer cell lines, SKOV3 and OVCAR-3. Conversely, down-regulation of CXCL1 in these cell lines inhibited cell proliferation, this effect being reversed by exogenous recombinant CXCL1. These data demonstrating a growth stimulatory activity of CXCL1 are in agreement with studies in other cancer cell types including melanoma (Richmond et al. 1983, 1985, Bordoni et al. 1989, 1990, Shattuck et al. 1994, Luan et al. 1997), squamous cell carcinomas (Loukinova et al. 2000), colon (Li et al. 2004), oesophageal (Wang et al. 2006) and oral cancers (Shintani et al. 2004).

CXCL1 binds and signals through the GPCR, CXCR2 (Mueller et al. 1994), as confirmed by our demonstration that blocking CXCR2 with SB225002 inhibited CXCL1-induced proliferation. There is considerable evidence to support the existence of crosstalk between GPCRs and receptor tyrosine kinases. Transactivation of the EGFR by a number of GPCR ligands has been demonstrated, including thrombin, angiotensin, lysophosphatidic acid (Rozengurt 2007, Bhola & Grandis 2008) and IL8, in many tissue types (Schraufstatter et al. 2003, Itoh et al. 2005, Luppi et al. 2007) including ovarian cancer (Venkatakrishnan et al. 2000).

IL8 signals through both the CXCL1 receptor CXCR2 and the related receptor CXCR1 (Lee et al. 1992); however, a previous study in ovarian cancer did not identify which receptor mediated IL8 transactivation of the EGFR (Venkatakrishnan et al. 2000). In the present study, we investigated whether CXCL1 may also induce EGFR transactivation and lead to increased ovarian cancer cell proliferation. CXCL1 stimulation of SKOV3 cells increased phosphorylation of the EGFR at Y1068, and inhibition of the EGFR by PD153035 decreased both CXCL1-induced phosphorylation of the EGFR at Y1068 and cell proliferation, suggesting that CXCL1-induced proliferation of EOC cells occurs through transactivation of the EGFR.

In our previous study, we found that EGF activation of the PI3-K pathway, leading to Akt phosphorylation, induced expression of CXCL1 (Moscova et al. 2006), suggesting a possible positive feedback loop where CXCL1 may regulate its own production through EGFR signalling. Since Akt pathway activity is associated with cell survival (Qiao et al. 2008), such a positive feedback might be strongly tumorigenic. However, phosphorylation of Akt at S473 was not detected following CXCL1 treatment, despite EGFR activation, indicating that a CXCL1-induced positive feedback loop through the PI3-K pathway is unlikely.

Chemokines have been well described to activate several pathways in addition to PI3-K signalling, such as the MAPK/ERK1/2 pathway (Venkatakrishnan et al. 2000, Xia & Hyman 2002, Wang et al. 2006, Rozengurt 2007, Waugh & Wilson 2008). CXCL1 induced ERK1/2 phosphorylation, which was blocked by the MEK1 inhibitor, PD98059. Furthermore, inhibition of CXCL1-induced ERK1/2 phosphorylation was inhibited by inhibition of the EGFR with
PD153035 and the pan-MMP inhibitor GM6001, suggesting that CXCL1-induced ERK1/2 activation occurred downstream of transactivation of the EGFR. The involvement of MAPK signalling in CXCL1-induced proliferation of EOC was further demonstrated by the inhibition of proliferation of EOC by both PD98059 and the farnesyltransferase inhibitor FTI-277, which blocks Ras activity (Lerner et al. 1995). Activation of ERK1/2 by CXCL1 has previously been reported in other cell types including astrocytes (Filipovic & Zecevic 2008), neutrophils (Fuhler et al. 2005) and neurons (Xia & Hyman 2002). IL8 has also been shown to stimulate ERK1/2 phosphorylation in SKOV3 cells (Venkatakrishnan et al. 2000). Given that IL8 and CXCL1 can signal through a common receptor, CXCR2, it is perhaps not surprising that treatment of cells with CXCL1 also leads to increased ERK1/2 phosphorylation. Cellular proliferation mediated by MAPK signalling has been well described (Rozengurt 2007), but this is the first report to describe the involvement of MAPK signalling in CXCL1-induced proliferation of EOC.

Our data suggest that transactivation of the EGFR by CXCL1 leads to activation of MAPK signalling, given that a peak of CXCL1-induced Y1068 EGFR phosphorylation was seen at 5 min, prior to the peak of ERK1/2 phosphorylation. Inhibition of MEK1 activity had no effect on EGFR phosphorylation, also consistent with MAPK activation occurring downstream of the EGFR (Meloche & Pouyssegur 2007). A second, slower wave of EGFR tyrosine phosphorylation seen 1–2 h after CXCL1 addition was not reflected in a second wave of ERK1/2 phosphorylation, suggesting that ERK phosphatases may still be active at this time. One mechanism of activation of MAPK signalling through GPCRs is mediated through the protein kinase C (PKC) pathway (Rozengurt 2007). We have recently described gonadotropin-induced EOC cell migration and proliferation through ERK1/2 activation, regulated by PKCδ (Mertens-Walker et al. 2010). It is therefore possible that PKCs may also play a role in CXCL1-induced MAPK signalling.

Transactivation of the EGFR can be mediated either by intracellular signalling via Src (Andreev et al. 2001, Guerrero et al. 2004, Li et al. 2006) or through extracellular MMP-mediated release of EGFR ligands such as TGF-α (McCole et al. 2002), amphiregulin (Gschwind et al. 2003) or HB-EGF (Prenzel et al. 1999, Itoh et al. 2005). The lack of effect of CXCL1 on Src phosphorylation, the lack of activation of phosphorylation at the Y845 site of EGFR known to be mediated by Src and the inhibitory effect of the pan-MMP inhibitor GM6001 on CXCL1-induced cell proliferation all suggest that CXCL1-induced EGFR transactivation is mediated through the extracellular signalling pathway.

Recently, HB-EGF has been implicated as a promising target for therapy for many cancer types, including ovarian cancer (Miyamoto et al. 2004, Yagi et al. 2005, 2008, Yotsumoto et al. 2008). Treatment of both SKOV3 and OVCAR-3 cells with an anti-HB-EGF neutralising antibody inhibited CXCL1-induced cell proliferation, confirming this potential mechanism of EGFR transactivation by CXCL1. Consistent with this is the demonstration of MMP release of HB-EGF to transactivate the EGFR by IL8 in both colon carcinoma (Itoh et al. 2005) and endothelial cells (Schaufstatter et al. 2003). It is possible that other EGFR ligands, apart from HB-EGF, will also have roles in CXCL1-mediated cellular proliferation of ovarian cancer.

In summary, our results have shown that CXCL1 induces EOC cell proliferation and that this occurs through CXCR2 activation, HB-EGF release from the plasma membrane by an MMP-like enzyme, EGFR autophosphorylation and Ras–ERK activation. Since both in vitro (Moscova et al. 2006) and in vivo (Lee et al. 2006, Yang et al. 2006, Wang et al. 2008) studies suggest a role for CXCL1 in EOC, our findings point to potential therapeutic targets for this disease.

Supplementary data

This is linked to the online version of the paper at http://dx.doi.org/10.1677/ERC-10-0107.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the Cancer Council NSW (Grant ID: 402640), the Cancer Institute NSW, Australia (Fellowship to D J Marsh), and the Watson Ovarian Cancer Research Fund.

References


Carpenter G 1999 Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways. Journal of Cell Biology 146 697–702. (doi:10.1083/jcb.146.4.697)


Xia M & Hyman BT 2002 GROalpha/KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation – a role in Alzheimer’s disease? *Journal of Neuroimmunology* 122 55–64. (doi:10.1016/S0165-5728(01)00463-5)


